Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 5Recurrence 2Lymphoma, T-Cell, Peripheral 2Lymphoma 2Immunoblastic Lymphadenopathy 2Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 3fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mycophenolic Acid 2Busulfan 2Biopsy 2talimogene laherparepvec 1pembrolizumab 1fludarabine 1duvelisib 1Vincristine 1Transplantation 1Sirolimus 1Radiotherapy 1Prednisone 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Gemcitabine 1Etoposide 1Cyclosporine 1Brentuximab Vedotin 1Blood Specimen Collection 1Aclarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sezary Syndrome × duvelisib × 90 days × Clear all
NCT04652960 2026-05-13

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

National Cancer Institute (NCI)

Phase 1 Active not recruiting
38 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡